Phase II study of cisplatin, irinotecan, and bevacizumab (NSC 704865 IND 7921) for untreated extensive stage small cell lung cancer: a phase II study
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 17 Jun 2014 Biomarkers information updated
- 07 Mar 2013 Primary endpoints added as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.